Read by QxMD icon Read

Docetaxel carboplatin breast cancer triple negative

Priyanka Sharma, Sara López-Tarruella, Jose Angel García-Saenz, Claire Ward, Carol Connor, Henry L Gómez, Aleix Prat, Fernando Moreno, Yolanda Jerez-Gilarranz, Agustí Barnadas, Antoni Picornell, Maria Del Monte-Millán, Milagros Gonzalez-Rivera, Tatiana Massarrah, Beatriz Pelaez-Lorenzo, María Isabel Palomero, Ricardo González Del Val, Javier Cortes, Hugo Fuentes Rivera, Denisse Bretel Morales, Iván Márquez-Rodas, Charles M Perou, Jamie Wagner, Joshua M V Mammen, Marilee McGinness, Jennifer R Klemp, Amanda Amin, Carol J Fabian, Jaimie Heldstab, Andrew K Godwin, Roy A Jensen, Bruce F Kimler, Qamar J Khan, Miguel Martin
PURPOSE: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxane chemotherapy improves pathological complete response (pCR) in triple negative breast cancer (TNBC). Effectiveness of anthracycline-free, platinum combinations in TNBC is not well known. Here we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC. PATIENTS AND METHODS: The study population includes 190 patients with stage I-III TNBC treated uniformly on two independent prospective cohorts...
June 14, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Neelima Denduluri, Mark R Somerfield, Andrea Eisen, Jamie N Holloway, Arti Hurria, Tari A King, Gary H Lyman, Ann H Partridge, Melinda L Telli, Maureen E Trudeau, Antonio C Wolff
PURPOSE: A Cancer Care Ontario (CCO) guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer including adjuvant targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancers was identified for adaptation. METHODS: The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for adapting clinical practice guidelines developed by other organizations. The CCO guideline was reviewed for developmental rigor and content applicability...
July 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Milagros González-Rivera, Miriam Lobo, Sara López-Tarruella, Yolanda Jerez, María del Monte-Millán, Tatiana Massarrah, Rocío Ramos-Medina, Inmaculada Ocaña, Antoni Picornell, Sonia Santillán Garzón, Lucía Pérez-Carbornero, José A García-Saenz, Henry Gómez, Fernando Moreno, Iván Márquez-Rodas, Hugo Fuentes, Miguel Martin
We describe the status and frequency of germline DNA genetic findings in an unselected prospective cohort of triple negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Study population includes 124 consecutive patients with stage II-III TNBC from a trial exploring the antitumor activity of neoadjuvant carboplatin/docetaxel chemotherapy enrolled between 2012 and March 2015, to determine the frequency of germline DNA genetic mutations. 17.1 % of the patients with germline DNA tested had deleterious mutations in any of the analyzed genes (12...
April 2016: Breast Cancer Research and Treatment
Aleix Prat, Estela Pineda, Barbara Adamo, Patricia Galván, Aranzazu Fernández, Lydia Gaba, Marc Díez, Margarita Viladot, Ana Arance, Montserrat Muñoz
Gene-expression profiling has had a considerable impact on our understanding of breast cancer biology. During the last 15 years, 5 intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched, Basal-like and Claudin-low) have been identified and intensively studied. In this review, we will focus on the current and future clinical implications of the intrinsic molecular subtypes beyond the current pathological-based classification endorsed by the 2013 St. Gallen Consensus Recommendations...
November 2015: Breast: Official Journal of the European Society of Mastology
Peter Kern, Anne Kalisch, Gunter von Minckwitz, Carolin Pütter, Hans-Christian Kolberg, Dirk Pott, Christian Kurbacher, Mahdi Rezai, Rainer Kimmig
INTRODUCTION: Triple-negative breast cancer (TNBC) has the highest mortality rates of all subtypes. Anthracycline and taxane regimens yield unsatisfactorily low rates of pathologic complete response (pCR) and are often not feasible in cardiac comorbidity. This study seeks to increase pCR and survival by introducing platin agents. PATIENTS AND METHODS: In this multicentric, open-label study with six cycles of docetaxel (75 mg/m(2)) and carboplatin AUC 6 q3w, patients were unwilling or unsuitable for anthracycline-based regimens...
June 2016: Journal of Chemotherapy
Melinda Telli
Although not yet practice changing in early-stage triple-negative breast cancer, growing evidence suggests that neoadjuvant platinum-based therapy is active and that some patients may benefit from such an approach. Recent randomized phase III data suggests that carboplatin has comparable efficacy to docetaxel as first-line therapy in unselected advanced triple-negative breast cancer. In both settings, the efficacy of such treatment appears to be influenced by BRCA1/2 mutation status, with carriers of these mutations experiencing higher response rates...
May 2015: Journal of the National Comprehensive Cancer Network: JNCCN
Ines Vaz-Luis, Melissa E Hughes, Angel M Cronin, Hope S Rugo, Stephen B Edge, Beverly Moy, Richard L Theriault, Michael J Hassett, Eric P Winer, Nancy U Lin
BACKGROUND: Among patients with stage I breast cancer, there is significant uncertainty concerning the optimal threshold at which to consider chemotherapy, and when considered, there is controversy regarding whether to consider non-intensive versus intensive regimens. The authors examined the types and costs of adjuvant chemotherapy received among patients with stage I breast cancer. METHODS: The current study was a prospective cohort study including patients with stage I breast cancer who were treated at a National Comprehensive Cancer Network center from 2000 through 2009...
June 15, 2015: Cancer
William M Sikov
As anticipated by their structure and mechanism of action, platinum analogs exhibit clinically significant antitumor activity in the more aggressive forms of breast cancer, both alone and in combination with other cytotoxic agents and targeted therapies. In early-stage human epidermal growth factor receptor-2 (HER2)-positive breast cancer, the administration of carboplatin together with a taxane (usually docetaxel) and trastuzumab (and pertuzumab in the neoadjuvant setting) is a standard of care regimen. In BRCA1 mutation carriers, neoadjuvant treatment with single-agent cisplatin results in a high pathologic complete response (pCR) rate...
February 2015: Current Oncology Reports
Hiroshi Tsubamoto, Takashi Sonoda, Kayo Inoue
BACKGROUND/AIM: Recurrent triple-negative breast cancer (TNBC) patients have poor prognoses and limited treatment options, especially after progression during prior chemotherapy. The present study aimed to determine the impact of itraconazole with chemotherapy in these patients. PATIENTS AND METHODS: Medical records of recurrent TNBC patients receiving itraconazole with chemotherapy between 2008 and 2012 were retrospectively reviewed. RESULTS: Thirteen patients who progressed during prior chemotherapy (12 with visceral organ metastases) were enrolled...
July 2014: Anticancer Research
Peter Kern, Anne Kalisch, Hans-Christian Kolberg, Rainer Kimmig, Friederich Otterbach, Gunter von Minckwitz, William M Sikov, Dirk Pott, Christian Kurbacher
BACKGROUND: Triple-negative breast cancer (TNBC) attracts a disproportionate share of intensive research because of its poor prognosis. Standard anthracycline- and taxane-based regimens still yield an unsatisfactorily low rate of pathologic complete response (pCR). The pCR rate is a recognized surrogate marker for good long-term survival. METHODS: A multicentric, retrospective study was conducted including all patients not willing to undergo or not suitable for an anthracycline-based regimen...
2013: Chemotherapy
Patrizia Vici, Laura Pizzuti, Teresa Gamucci, Domenico Sergi, Francesca Conti, Germano Zampa, Pietro Del Medico, Roy De Vita, Marcello Pozzi, Claudio Botti, Simona Di Filippo, Federica Tomao, Isabella Sperduti, Luigi Di Lauro
PURPOSE: Chemotherapy regimens containing anthracyclines and taxanes represent the landmark of neoadjuvant systemic therapy of breast cancer. In advanced breast cancer patients liposomal anthracyclines (LA) have shown similar efficacy and less cardiac toxicity when compared to conventional anthracyclines. We performed this retrospective analysis in order to evaluate the efficacy and tolerability of neoadjuvant regimens including LA outside of clinical trials in routine clinical practice...
2014: Journal of Cancer
Ying Sun, Huan Ding, Xiao-qing Li, Li Li
OBJECTIVE: To observe the effects of poly(ADP-ribose)polymerase (PARP) inhibitor AG014699 alone and combined with docetaxel (DTX) or carboplatin (CBP) on the proliferation of triple-negative breast cancer cell line MDA-MB-231 and to investigate whether PARP inhibitor AG014699 combined with chemotherapy could play a synergistic antitumor effect. METHODS: MDA-MB-231 cells were treated by PARP inhibitor AG014699 alone or combination with DTX or CBP. Cell proliferation was measured by cell counting kit-8 assay...
April 2014: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
Stina M Singel, Crystal Cornelius, Elma Zaganjor, Kimberly Batten, Venetia R Sarode, Dennis L Buckley, Yan Peng, George B John, Hsiao C Li, Navid Sadeghi, Woodring E Wright, Lawrence Lum, Timothy W Corson, Jerry W Shay
Despite evidence that kinesin family member 14 (KIF14) can serve as a prognostic biomarker in various solid tumors, how it contributes to tumorigenesis remains unclear. We observed that experimental decrease in KIF14 expression increases docetaxel chemosensitivity in estrogen receptor-negative/progesterone receptor-negative/human epidermal growth factor receptor 2-negative, "triple-negative" breast cancers (TNBC). To investigate the oncogenic role of KIF14, we used noncancerous human mammary epithelial cells and ectopically expressed KIF14 and found increased proliferative capacity, increased anchorage-independent grown in vitro, and increased resistance to docetaxel but not to doxorubicin, carboplatin, or gemcitabine...
March 2014: Neoplasia: An International Journal for Oncology Research
Francesco Recchia, Giampiero Candeloro, Alisia Cesta, Mario DI Staso, Pierluigi Bonfili, Giovanni Luca Gravina, Ernesto DI Cesare, Stefano Necozione, Silvio Rea
The present study aimed to determine the toxicity and efficacy of 4 courses of anthracyclines-taxane (AT) chemotherapy followed by radiation therapy (XRT) concurrent with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in surgically resected axillary node-positive (N+) breast cancer. A total of 200 women with N+ breast cancer were treated with adriamycin and docetaxel followed by XRT concurrent with six courses of CMF. Two courses of dose-dense chemotherapy with ifosfamide, carboplatin and etoposide, supported by pegfilgrastim, were administered to patients with >5 histologically confirmed axillary lymph node metastases and patients with triple-negative disease...
May 2014: Molecular and Clinical Oncology
Judith Hurley, Isildinha M Reis, Steven E Rodgers, Carmen Gomez-Fernandez, Jean Wright, Jose Pablo Leone, Rene Larrieu, Mark D Pegram
Triple-negative breast cancers comprise about 20 % of breast cancers. They have poor prognosis and have no standard therapy. The aim of this study was to evaluate pathologic complete response (pCR), progression-free survival (PFS), and overall survival (OS) in patients with TNBC treated with neoadjuvant platinum-based chemotherapy. This is a retrospective study of one hundred and forty-four women with TNBC treated with neoadjuvant platinum-containing chemotherapy for locally advanced breast cancer at the University of Miami between January 1, 1999, and January 1, 2011...
April 2013: Breast Cancer Research and Treatment
H R Kim, K H Jung, S-A Im, Y-H Im, S Y Kang, K H Park, S Lee, S-B Kim, K-H Lee, J S Ahn, S I Kim, J H Sohn
BACKGROUND: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer. PATIENTS AND METHODS: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-negative, stage II/III breast cancer received six cycles of 75 mg/m(2) docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN)...
June 2013: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Francesco Recchia, Giampiero Candeloro, Giovambattista Desideri, Stefano Necozione, Cornelia O C Recchia, Vincenzo Cirulli, Silvio Rea
Anthracyclines (A) and taxanes (T) are standard first-line chemotherapy agents for patients with advanced breast cancer. Platinum analogues have also shown activity in the triple-negative breast cancer (TNBC) histology, but clinical data are limited. Here we report the long-term follow-up of a phase II study on TNBC treated with a combined modality therapy, including induction with AT, cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with concurrent radiation therapy, and a dose-dense consolidation chemotherapy (HDCT) with carboplatin (CBDCA), ifosfamide (IFX), etoposide (VP-16)...
August 2012: Cancer Medicine
Peng Yuan, Bing-he Xu, Jia-yu Wang, Fei Ma, Qing Li, Pin Zhang, Ying Fan, Qiao Li, Wen-miao Wang
OBJECTIVE: Triple-negative [estrogen receptor (ER)-/progesterone receptor (PR)-/HER2-] breast cancer (TNBC) accounts for ∼ 15% of overall breast cancer and associated with a poor prognosis. There is a short of standard adjuvant chemotherapy regimens for TNBC. A number of studies have shown that TNBC might be sensitive to cisplatin and carboplatin on the basis that dysfunction of BRCA1 and its pathway is associated with a specific DNA-repair defect, but data of adjuvant setting about this is limited...
June 2012: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
Vivek Roy, Barbara A Pockaj, Jacob B Allred, Heidi Apsey, Donald W Northfelt, Daniel Nikcevich, Bassam Mattar, Edith A Perez
OBJECTIVE: We conducted a multicenter phase II trial to assess the efficacy and toxicity of docetaxel and carboplatin combination as neoadjuvant therapy for stage II or III breast cancer (BC). METHODS: Patients received 75 mg/m of docetaxel and AUC 6 of carboplatin on day 1 followed by pegfilgrastim on day 2, every 14 days for 4 cycles, followed by definitive breast surgery. The primary endpoint was the proportion of patients achieving pathologic complete remission (pCR), defined as disappearance of all invasive and in situ tumors in the breast and axilla after chemotherapy...
December 2013: American Journal of Clinical Oncology
Minhao Lv, Beibei Li, Yongfeng Li, Xiaoyun Mao, Fan Yao, Feng Jin
INTRODUCTION: Breast cancer is increasingly regarded as a heterogeneous disease which can be classified into distinct molecular subtypes with prognostic significance. MATERIALS AND METHODS: ER, PR, HER2 and ki-67 were used to divided 102 breast cancers treated with neoadjuvant chemotherapy (NCT) into 4 subtypes: luminal A (ER+, PR+, HER2-, and ki-67≤14%), luminal B (ER+, PR+, HER2- and ki-67>14% ; ER+ and/or PR+, HER2+), HER2-overexpression (ER-, PR- and HER2+) and triple-negative (ER-, PR-, and HER2-)...
2011: Asian Pacific Journal of Cancer Prevention: APJCP
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"